<DOC>
	<DOC>NCT01925950</DOC>
	<brief_summary>Use of an oral topically-active glucocorticoid with limited side effects may control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.</brief_summary>
	<brief_title>Study of orBecÂ® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Receipt of allogeneic hematopoietic cell transplant &gt;100 days prior to consent Documented cGVHD as defined by the NIH consensus criteria in at least one organ system other than the GI tract (for example, cGVHD of the oral cavity would qualify as a criterion) Endoscopic findings consistent with GI GVHD Must be able to swallow tablets Must be able to read and understand informed consent Adequate birth control methods for the duration of the study &gt;500 mL/day of diarrhea on any 1 day within 3 days prior to the first dose of study drug GI infection Multiorgan failure or other condition that, in the opinion of the investigator, would compromise the patient's ability to complete the study. HIV seropositivity Pregnant or nursing female Use of any investigational drug to treat chronic GVHD within 28 days of the first dose of study drug Evidence of recurrent or progressing malignant disorder that was the indication for HCT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>BDP</keyword>
	<keyword>orBec</keyword>
	<keyword>GVHD</keyword>
	<keyword>beclomethasone dipropionate</keyword>
	<keyword>bone marrow transplant</keyword>
	<keyword>hematopoietic cell transplant</keyword>
	<keyword>HCT</keyword>
	<keyword>stem cell transplant</keyword>
	<keyword>marrow transplant</keyword>
	<keyword>SCT</keyword>
	<keyword>beclomethasone 17,21-dipropionate</keyword>
</DOC>